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or the past half-century or so,the US Food and
Drug Administration (FDA) has licensed drugs for use
in schizophrenia only if they reduced the positive symp-
toms of psychosis. This limitation was identified as a
bottleneck preventing the identification and develop-
ment of novel treatments for the problems experienced
by schizophrenia patients.
1,2 Implicitly, the FDA oper-
ated from the assumption that one must treat the entire
disorder with one compound, rather than treat specific
clinical problems with specific compounds. It has
become widely accepted that a cluster of cognitive
deficits—which have been long recognized as being
important aspects of schizophrenia—are not treated
adequately, if at all, by existing antipsychotic treat-
ments.
2,3 Furthermore, evidence has accumulated that
these cognitive deficits are largely responsible for the
disappointingly poor functional outcome demonstrated
9
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Prepulse inhibition of startle (PPI), a measure of sensorimotor gating used to identify antipsychotics, is reduced in schiz-
ophrenia patients and in rodents treated with dopamine agonists or glutamate antagonists. The National Institute of
Mental Health (NIMH)–funded Measurement And Treatment Research to Improve Cognition in Schizophrenia (MATRICS)
program has initiated a new era in the development of procognitive cotreatments in schizophrenia, independently of
treating positive symptoms. Although PPI is not a cognitive process per se, such abnormalities in attention may be pre-
dictive of or lead to cognitive deficits. Since first-generation antipsychotics block PPI deficits induced by dopamine ago-
nists, this model cannot identify cognitive enhancers for use as cotreatments with antipsychotics. PPI deficits caused by
glutamate antagonists, like the exacerbation of symptoms they produce in patients, are insensitive to dopamine antag-
onists, but reduced by clozapine. Similarly, both PPI and cognitive deficits in schizophrenia patients are insensitive to first-
generation antipsychotics, but attenuated by clozapine. Hence, treatment-induced reversals of glutamate antagonist
effects on PPI may provide animal and human models to identify treatments of cognitive deficits in patients already
treated with existing antipsychotics.    
© 2006, LLS SAS Dialogues Clin Neurosci. 2006;8:9-16.by antipsychotic-treated patients with schizophrenia.
4
Thus, despite the fact that many antipsychotic treat-
ments have been identified and licensed, the cognitive
deficits remain as clinical problems in schizophrenia,
and most patients cannot work.
The MATRICS program
MATRICS: moving beyond antipsychotics
In response to the identification of the bottleneck lim-
iting the development of treatments specifically
directed at the cognitive deficits in schizophrenia, the
US National Institute of Mental Health (NIMH) devel-
oped the Measurement And Treatment Research to
Improve Cognition in Schizophrenia (MATRICS) pro-
gram.MATRICS set out to develop a broad consensus
regarding the nature of the cognitive impairments in
schizophrenia and how they might best be assessed and
treated.
5The MATRICS approach to the problem is to
treat cognitive deficits and psychotic symptoms sepa-
rately.The NIMH awarded the MATRICS contract to
the University of California Los Angeles (UCLA) (Drs
Stephen Marder and Michael Green, Co-principal
Investigators) in 2002. Over the subsequent 2 years,
MATRICS gathered the relevant stakeholders in both
industry and academia to achieve a consensus and
establish a clear path that would enable the FDA to
consider registering compounds intended to treat cog-
nitive deficits in schizophrenia,independently of treat-
ing psychosis per se.The typical anticipated use of such
compounds would be as cotreatments in schizophrenia
patients who were already treated with antipsychotic
medications.Hence,the assumption has been that these
patients would be relatively free of the positive symp-
toms of schizophrenia that might complicate the assess-
ment of cognitive deficits and impede the ability of
patients to benefit from cognitive enhancers.
The MATRICS consensus process
MATRICS consisted of a series of conferences orga-
nized by corresponding committees of experts.The first
step was taken by the MATRICS Neurocognition
Committee, which organized a 2-day consensus meet-
ing in April 2003 in order to identify the critical
domains of cognitive deficits that characterize patients
with schizophrenia.
6 The seven domains of cognition
deemed most relevant in schizophrenia were: working
memory;attention/vigilance;verbal learning and mem-
ory; visual learning and memory; speed of processing;
reasoning and problem-solving;and social cognition.At
the second MATRICS meeting, held at the National
Institutes of Health (NIH) in June of 2003, the
Neuropharmacology Committee assembled clinicians
and psychopharmacologists from academia and indus-
try to identify the most intriguing molecular targets,
promising compounds, relevant human test measures,
and potentially predictive animal models for use in the
discovery of treatments that target basic mechanisms
related to complex cognitive operations.The presenta-
tions at that meeting were gathered in a special issue of
Psychopharmacology.
7 A third MATRICS conference
then used the consensus process developed by RAND
Health to develop recommendations for the appropri-
ate cognitive tests to be used in clinical assessments of
potential cognitive enhancers.The meeting resulted in
a beta version of the MATRICS Consensus Cognitive
Battery for Clinical Trials, which is listed on the
MATRICS Web site.
8,9 The next MATRICS meeting
was held at the NIMH in January 2004 and focused on
collaborations between the NIMH and industry. The
fifth MATRICS conference involved a joint meeting
between the FDA and the NIMH, and addressed the
processes needed for assessment of cognition as an end
point in clinical trials.This meeting was held at the NIH
in April 2004 and was summarized in Buchanan et al.
10
Once the primary consensus-building goals of
MATRICS were accomplished, a concluding meeting
called “New Approaches to Assessing and Improving
Cognition in Schizophrenia”was held in Potomac,Md,
in September 2004.This meeting was designed to look
ahead in order develop a research agenda that would
foster improved methods for the discovery, validation,
and assessment of procognitive cotreatments for schiz-
ophrenia (for transcripts of the presentations, see the
MATRICS Web site
9). The proceedings of this last
MATRICS conference were summarized in a special
issue of Schizophrenia Bulletin.
11Throughout the 2-year
process, the MATRICS conferences included partici-
pants from the NIMH, the NIH, and the FDA, as well
as academic and industry representatives,and were very
effective in establishing a broad consensus regarding
the appropriate criteria and opportunities for discover-
ing and evaluating cotreatments for the cognitive
impairments in schizophrenia.
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Gating deficits in schizophrenia
Measures of sensory or sensorimotor gating are among
the most widely studied physiological markers used in
laboratory studies of schizophrenia. For example, the
auditory “sensory gating” paradigm pioneered by
Freedman’s group involves a condition-test,paired-stim-
ulus paradigm in which the P50 event-related potential
(ERP) elicited by the second of two audible clicks is nor-
mally reduced relative to the ERP elicited by the first
click.
12 In schizophrenia patients,however,this suppres-
sion of the P50 is diminished,apparently due to a reduc-
tion in short-term habituation.An analogous paradigm
has been developed for use in rodents.
13 This cross-
species ERP paradigm has been critical in the identifica-
tion of the α7-nicotinic receptor as a potential target for
procognitive cotreatments in schizophrenia.
13
Another cross-species gating paradigm,prepulse inhibi-
tion of startle (PPI) is the focus of this review and differs
qualitatively from the P50 ERP paradigm. Since it
involves both sensory stimuli and motor responses,PPI
is considered a measure of “sensorimotor gating”rather
than sensory gating.
14,15 In PPI, the startle response
elicited by a strong sudden stimulus,usually acoustic or
tactile,is measured in the presence or absence of a weak
prepulse stimulus,which may be in the same or a differ-
ent modality. The weak prepulse robustly inhibits the
response to the subsequent startling stimulus.In contrast
to P50 suppression,PPI is clearly not a form of habitua-
tion. In humans, startle is usually assessed via the eye-
blink component of startle,using electromyography.In
animals, the whole-body flinch aspect of the startle
response is quantified using an accelerometer that is sen-
sitive to dynamic movements.
As was first noted by Braff and colleagues in 1978
16 and
confirmed in many subsequent reports,
17 PPI is reduced in
schizophrenia patients.The early demonstrations of PPI
deficits in schizophrenia were based on groups of patients
who were,for the most part,treated with first-generation
or so-called typical antipsychotic drugs.More recent stud-
ies have demonstrated similar deficits even in first-break
patients who had never been treated with any antipsy-
chotics.
18Thus,deficient PPI in schizophrenia is not attrib-
utable to medications or the course of illness,but it is also
not reversed by first-generation antipsychotic treatments.
Sensorimotor gating deficits in psychiatric disorders
Studies of PPI as an operational measure of sensorimo-
tor gating were originally intended to test the general
theory that failures of inhibitory filtering mechanisms can
lead to sensory overload and consequent cognitive frag-
mentation in schizophrenia.
14,15 Nevertheless,subsequent
research has demonstrated that PPI is reduced not only
in schizophrenia, but also in patients suffering from a
variety of neuropsychiatric disorders characterized by
deficits in the gating of motor,sensory,and/or cognitive
information.
17Thus,PPI deficits have also been found in
obsessive-compulsive disorder (OCD),Tourette’s syn-
drome,Huntington’s disease,panic disorder,
19 and manic
patients with bipolar disorder.
20These disorders are all
characterized by PPI deficits and abnormalities of gating
in sensory,motor,or cognitive domains.It should also be
noted,however,that deficient PPI is not found in several
other psychiatric disorders.
17
Antipsychotic effects on PPI in animals
PPI models in rodents
The cross-species nature of startle and PPI enables the
use of animal models of induced deficits that are
extremely similar to the gating deficits seen in schizo-
phrenia.Beginning with the initial demonstrations of the
ability of dopamine agonists to disrupt PPI in rats, the
rodent PPI models have evolved into at least four distinct
models.
21These models have PPI measures in common,
but are differentiated by the manipulations used to dis-
rupt PPI:(i) psychostimulant dopamine agonists;(ii) hal-
lucinogenic serotonin agonists;(iii) psychotomimetic N-
methyl-D-aspartate (NMDA) receptor antagonists;and
(iv) developmental manipulations,such as isolation rear-
ing or neonatal lesions of the ventral hippocampus.The
first three models are based on changes induced by
acutely administered psychotomimetic drugs.While phar-
macological approaches that alter PPI help identify rel-
evant neural substrates,they do not assess environmen-
tal or developmental contributions to PPI deficits. In
contrast,the fourth PPI model is based on the loss of PPI
in adult rats subsequent to social isolation during devel-
opment.
22 Although this isolation rearing model has
proven to be of value in testing antipsychotic treat-
ments,
23 only the dopamine and NMDA models are par-
ticularly relevant for the present discussion.
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As reviewed in detail elsewhere,
21 PPI disruptions that
mimic those seen in schizophrenia were first produced in
animals by the administration of direct or indirect
dopamine agonists,such as apomorphine or d-ampheta-
mine.
24The original dopamine model focused primarily on
testing the ability of antipsychotic drugs to block the PPI-
disruptive effects of apomorphine in rats.
25 In brief,these
effects of apomorphine in rats are reliably prevented by
virtually all antipsychotics that have appreciable affinity
for dopamine D2 receptors.There is an excellent correla-
tion between the clinical potency of an antipsychotic and
its ability to block the PPI-disruptive effects of the
dopamine agonist apomorphine in rats.
25 Although this
finding provides important validation of the predictive
validity of the dopamine PPI model,it primarily reflects
the importance of D2 receptor antagonism in antipsychotic
drug action and therefore only recapitulates in a behav-
ioral paradigm what was already known from simple lig-
and-binding assays.Thus,the dopamine agonist PPI model
is an example of what might be termed “receptor tautol-
ogy,” insofar as the receptor mechanism of the agonist
used to induce the schizophrenia-like PPI deficit predicts
the antagonists that the behavioral test will identify.The
serotonin agonist PPI model suffers from the same logical
limitation; PPI disruptions by hallucinogenic serotonin
agonists largely provide only a model to identify antago-
nists at the serotonin (5-hydroxytryptamine) 5-HT2A
receptor because that is the receptor upon which the ago-
nists act.
21,26While such information may well be germane
to the actions of most second-generation antipsychotics,
such agonist-induced phenomena lead to circular models
that are not likely to lead to the identification of novel
mechanisms or treatments.
The NMDA antagonist PPI model
The rodent PPI model that shows the greatest potential to
provide insight into the unique effects of second- rather
than first-generation antipsychotics is the NMDA antago-
nist model.As reviewed elsewhere,
21 both competitive and
noncompetitive NMDA antagonists (eg, phencyclidine,
dizocilpine,and ketamine) produce robust deficits in PPI
in rats,mice,or infra-human primates.Many studies of the
effects of antipsychotics on the PPI-disruptive effects of
NMDA antagonists have confirmed that first-generation
antipsychotics such as haloperidol do not attenuate the
PPI-disruptive effects of NMDA antagonists in rats.
21,24
Similarly, the effects of NMDA antagonists on PPI are
maintained in mice treated with dopamine antagonists or
in mutant mice lacking specific subtypes of dopamine
receptors.
27,28 In contrast,clozapine and some other second-
generation antipsychotics have been demonstrated to
reduce the disruption in PPI produced by NMDA antag-
onists in both rats
21 and mice.
27,29This interaction between
clozapine and NMDA antagonists is seen only with a lim-
ited range of doses and has been confirmed in many,but
not all, studies in rats.
21 Complementing the studies in
rodents,clozapine has been demonstrated to attenuate the
effects of phencyclidine on PPI in monkeys, while
haloperidol was ineffective.
30These results in experimen-
tal animals are consistent with the observations in humans
that the psychotic symptoms produced by NMDA antag-
onists are not reduced by typical antipsychotics but are
blocked by clozapine.
31,32 Such findings led to the sugges-
tion that the phencyclidine-PPI model might enable the
specific identification of atypical rather than typical
antipsychotic treatments.
33
The interactions between second-generation antipsy-
chotics and NMDA antagonists with regard to their
effects on PPI are not likely to be mediated by compe-
tition for a common receptor, because these antipsy-
chotics do not have appreciable affinity for NMDA
receptors.Rather,the reductions in NMDA antagonist-
induced PPI deficits following clozapine-like antipsy-
chotics likely reflect interactions within the complex fore-
brain circuitry that modulates PPI.
34 Thus, the NMDA
antagonist PPI model does not appear to be another
instance of receptor tautology and may,therefore,pro-
vide a pathway to identification of novel molecular tar-
gets for treatments of schizophrenia.
PPI in the post-MATRICS era
By virtue of the MATRICS program,the new focus of
drug discovery in schizophrenia is on the identification
of potential procognitive cotreatments.In contrast,the
work discussed above addressed the effects of antipsy-
chotic treatments on PPI in animal models.In the post-
MATRICS era,the question arises as to the possible util-
ity of PPI models in the discovery process for
procognitive cotreatments.The previous work in rodents
indicated that the dopamine PPI model is reliably pre-
dictive of existing antipsychotics,while the NMDA PPI
model is insensitive to first-generation antipsychotics,but
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responsive to clozapine and some other second-genera-
tion compounds.Since the anticipated application is for
cotreatments to be used in patients already stably treated
with antipsychotic drugs, any animal model that is
responsive to first-generation antipsychotics is likely to
be uninformative.Given that the patients will already be
treated with antipsychotics having antagonist actions at
dopamine D2 receptors, dopamine agonist models are
inappropriate.In contrast,the PPI models based on the
effects of NMDA antagonists may be of considerable
value in this context.
Antipsychotic effects on PPI and cognition in patients
The fundamental difficulty in evaluating the potential
applicability of any animal model for the prediction of
procognitive agents in schizophrenia is the absence of
any established positive control compound.That is,in the
absence of any path to registration of procognitive treat-
ments that do not also treat positive symptoms of schiz-
ophrenia,virtually no studies have been done in this spe-
cific area. What we do have some information about,
however,are comparisons of different classes of antipsy-
chotic drugs on both cognition and PPI in patients with
schizophrenia.As summarized recently by Hagan and
Jones,
35 it is clear that first-generation antipsychotics,
which are principally dopamine D2 antagonists,have no
beneficial effects on cognition.Similarly,as evident from
the many early demonstrations of deficient PPI in
antipsychotic-treated patients, first-generation com-
pounds do not normalize PPI in schizophrenia.
21,36With
respect to second-generation antipsychotics,and in par-
ticular clozapine,the evidence is less clear,but indicates
that clozapine and some other multireceptor antagonist
antipsychotics may have some salutary influences on cog-
nition
37 and appear to be associated with relatively nor-
mal PPI.
36 Of particular interest in this regard is a cross-
sectional study indicating that clozapine treatment,
relative to typical antipsychotic treatments,is associated
with reduced PPI deficits in patients with schizophrenia.
38
While the evidence indicating that second-generation
antipsychotics,especially clozapine,may ameliorate PPI
deficits in schizophrenia is based largely on cross-sec-
tional studies,
35,38 some longitudinal studies are now sug-
gesting that PPI deficits may be reversed in groups of
schizophrenia patients treated primarily with second-
generation compounds.
39Although much more work is
needed to clarify the effects of newer antipsychotics on
both cognitive and PPI deficits in schizophrenia,it is clear
that first-generation antipsychotics fail to normalize
either class of deficits.
NMDA antagonist effects
The original suggestion that glutamatergic systems may
contribute to symptoms of schizophrenia derived from
the observation that NMDA receptor antagonists,such
as phencyclidine or ketamine,produce psychotic symp-
toms that resemble those seen in schizophrenia.
26,40,41 In
contrast to effects produced by dopamine agonists such
as amphetamine,which primarily resemble only the pos-
itive symptoms of schizophrenia,the effects of NMDA
antagonists have been suggested to mimic the positive,
negative,and cognitive symptoms of schizophrenia.
26,40-42
Further,administration of the NMDA receptor antago-
nist ketamine to schizophrenia patients exacerbates both
psychotic symptoms and cognitive impairments.
32With
respect to the cognitive deficits, it appears that, within
groups of schizophrenia patients,the most robust corre-
lates of the deficits in PPI are abnormalities in dis-
tractibility
43 and thought disorder.
44As noted above,the
PPI-disruptive effects of NMDA antagonists in rats and
mice are clearly insensitive to most first-generation
antipsychotic treatments,but are attenuated by clozap-
ine and some other second-generation antipsychotics.
21,29
Similarly, the psychotomimetic effects of ketamine in
humans are insensitive to first-generation antipsychotics
such as haloperidol,but are reduced in patients treated
with clozapine.
31,32 Hence,the rodent model based on the
disruption of PPI produced by NMDA antagonists may
reveal information that is specifically relevant to the
responsiveness of some neuroleptic-resistant patients to
second-generation antipsychotics such as clozapine.
Conclusions
The NIMH-funded MATRICS program has ushered in
a new era in the development of treatments for cognitive
deficits in schizophrenia,independently of treating psy-
chotic symptoms.Compounds to be used as cotreatments
in schizophrenia patients already treated with antipsy-
chotic drugs may now be registered.Animal models hav-
ing predictive validity for identifying existing antipsy-
chotics,including first-generation compounds,would not
appear to be useful here;these drugs do not ameliorate
the cognitive deficits in schizophrenia and most patientswill already be treated with them.Although PPI cannot
be considered to be a cognitive process per se, abnor-
malities in preattentive information processing may be
predictive of or even lead to complex cognitive deficits.
Rodent models mimicking the deficits in PPI seen in
schizophrenia, bipolar mania, and other disorders are
used to identify antipsychotics. Indeed, both first- and
second-generation antipsychotics reliably block the PPI
deficits induced by dopamine agonists. Hence, the
dopamine agonist PPI model is not useful in identifying
cognitive enhancers of relevance to schizophrenia. In
contrast,the PPI deficits caused by NMDA antagonists,
like the exacerbation of symptoms they produce in
patients,are insensitive to first-generation antipsychotics,
but are attenuated by clozapine.Similarly,PPI deficits in
schizophrenia patients, like cognitive deficits, are not
reversed by first-generation antipsychotics,but may be
attenuated by clozapine.Hence,treatment-induced rever-
sals of deficits in PPI produced by NMDA antagonists
may provide animal,and human,models to aid in the dis-
covery of treatments of cognitive deficits in patients
already treated with existing antipsychotics.
Given the absence of positive control compounds having
known efficacy in the treatment of cognitive deficits in
schizophrenia or bipolar disorder,especially when used
as cotreatments with existing antipsychotics,it is prema-
ture to establish the predictive validity of related animal
models.Nevertheless,the NMDA antagonist PPI model
may have heuristic value in this context due to its con-
struct validity related to cognitive deficits in attention
and information processing.
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¿Son útiles las mediciones de la selección de
impulsos sensomotores a través de las 
especies para el descubrimiento de coterapias
procognitivas en la esquizofrenia?   
La inhibición del alerta preestímulo (IAP), una
medida de la selección de impulsos  sensomotores
utilizada para identificar los antipsicóticos, está redu-
cida en los pacientes esquizofrénicos y en roedores
tratados con agonistas de dopamina o antagonistas
de glutamato. El programa MATRICS (Measurement
And Treatment Research to Improve Cognition in
Schizophrenia) financiado por el Instituto Nacional
de Salud Mental (NIMH) ha iniciado una nueva era
en el desarrollo de las coterapias procognitivas en la
esquizofrenia, independiente del tratamiento de los
síntomas positivos. Aunque la IAP no es un proceso
cognitivo per se, tales anormalidades en la atención
pueden ser predictoras de o conducir a déficits cog-
nitivos. Ya que los antipsicóticos de primera genera-
ción bloquean los déficits de la IAP inducidos por
agonistas de dopamina, este modelo no puede iden-
tificar reforzadores cognitivos para su empleo como
coterapias con antipsicóticos. Tanto los déficits de IAP
provocados por antagonistas de glutamato, como la
exacerbación de síntomas que ellos producen en los
pacientes, son insensibles a los antagonistas de dopa-
mina, pero se reducen con clozapina. Del mismo
modo, la IAP y los déficits cognitivos de los pacientes
esquizofrénicos son insensibles a los antipsicóticos de
primera generación, pero son atenuados por cloza-
pina. En consecuencia, la reversión de los efectos de
antagonistas de glutamato inducida por el trata-
miento sobre la IAP puede proveer modelos anima-
les y humanos para identificar terapias para los défi-
cits cognitivos en los pacientes que ya han sido
tratados con los antipsicóticos existentes.
Les mesures interespèces de modulation des
afférences sensorimotrices sont-elles utiles
pour la découverte des cotraitements 
procognitifs dans la schizophrénie ?
L’inhibition du sursaut par prépulse (IPP), un outil de
mesure de modulation des afférences sensorimo-
trices, utilisé pour identifier les antipsychotiques, est
diminuée chez les patients schizophrènes et les ron-
geurs traités par des agonistes dopaminergiques ou
des antagonistes du glutamate. Le programme
MATRICS (Measurement And Treatment Research to
Improve Cognition in Schizophrenia) financé par le
NIMH (National Institute of Mental Health), a inau-
guré une nouvelle ère dans le développement de
cotraitements procognitifs dans la schizophrénie,
indépendamment du traitement des symptômes
positifs. Bien que l’IPP ne soit pas un processus cogni-
tif en soi, des déficits de l’attention peuvent être pré-
dictifs de, ou mener à des déficits cognitifs. Les anti-
psychotiques de première génération bloquant les
déficits d’IPP induits par les dopaminergiques, ce
modèle ne reconnaît pas les stimulateurs de la cogni-
tion comme traitements associés aux antipsycho-
tiques. Les déficits d’IPP induits par les antagonistes
du glutamate, comme l’exacerbation des symptômes
qu’ils provoquent chez les patients, ne sont pas sen-
sibles aux antagonistes de la dopamine mais sont
diminués par la clozapine. De façon identique, l’IPP
et les déficits cognitifs chez les patients schizo-
phrènes ne sont pas sensibles aux antipsychotiques
de première génération mais sont diminués par la
clozapine. Par conséquent, des inversions des effets
antagonistes du glutamate sur l’IPP induites par un
traitement peuvent constituer des modèles animaux
et humains pour identifier des traitements des défi-
cits cognitifs chez des patients déjà traités avec des
antipsychotiques existants.
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